Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Anora closes the acquisition of Globus Wine A/S

Anora Group Plc   Press release   1 July 2022 at 1:30 pm EET Anora closes the acquisition of Globus Wine A/S Anora has today closed the acquisition of Globus Wine A/S, the leading wine company in Denmark. The acquisition was announced on 22 June 2022. As a continuation to the merger last fall, the acquisition of Globus Wine strengthens Anora’s position as the leading wine supplier in the Nordics. With the acquisition, Anora will become the market leader in the Danish wine market in addition to its leading position in the other three Nordic countries. Furthermore, the acquisition

Invitation to conference call and webcast presentation of Dometic’s interim report for the second quarter 2022

Dometic Group AB (publ) will publish its interim report for the second quarter 2022 at around 08.00 CEST on Friday, July 15, 2022. On the same day at 10.00 CEST, Dometic will host a conference call and webcast to present the results. The presentation can be followed live via webcast and will also be available afterwards. The presentation will be held in English. The report and the presentation material will be available on Dometic’s website, https://www.dometicgroup.com/en/investors 

Capital Markets Update and second quarter 2022 presentation

NRC Group ASA is pleased to invite investors, analysts, media and other stakeholders to its Capital Markets Update and second quarter 2022 presentation on Thursday 18 August.  The company will provide an update on NRC Group’s strategy, operations, markets, financial development and outlook. The second quarter 2022 results will be published the same day and presented at the event. The presentations will be given in English. Place: House of Oslo, Ruseløkkveien 34, Oslo, and live stream Date: 18[th] of August 2022 Time: 10:00 – 12:00 am CET A detailed programme will be announced

The Board of Directors of NoHo Partners Plc has decided on a directed share issue as a part of the acquisition of all the shares in Sea Horse Oy

NoHo Partners Plc STOCK EXCHANGE RELEASE 1 July 2022 at 1 p.m. The Board of Directors of NoHo Partners Plc has decided on a directed share issue as a part of the acquisition of all the shares in Sea Horse Oy The board of directors of NoHo Partners Plc (“NoHo Partners”) has today, by virtue of an authorisation granted by the company’s annual general meeting on 27 April 2022, decided to issue 170,728 new shares (“New Shares”) in a directed share issue. The New Shares correspond to approximately 0.83 per cent of all shares in NoHo Partners before the share issue. The share issue

DSRT: Purchase of shares by CEO

ISSUER DESERT CONTROL AS Sandnes, Norway, 1 July 2022: CEO of Desert Control AS ("Desert Control" or the"Company") has on 1 July 2022 purchased shares in the company.On 1 July 2022, Ole Kristian Sivertsen, CEO of the Company, has through OKSConsulting AS purchased 1 000 shares in the Company at an average price of NOK27.00. Following the transaction, OKS Consulting AS holds a total of 803 500shares in the Company.Primary insider notification pursuant to the market abuse regulation article 19are attached.For further information, please contact:Erling Rasmussen, Chief

DecideAct and Influenter partner to power up public sector execution

Never have so many reforms, laws, and local government strategies and plans been adopted. For society to reap the full benefits of policy reforms and strategies that address major societal challenges, the capacity of the public sector to implement and execute must be strengthened. That is why DecideAct A/S and Influenter A/S are now collaborating to digitize execution. This will create a better overview and management, less resource consumption for follow-up, and ensure that strategies and initiatives that are about to go off track can be corrected in time. The benefits are better citizen

Seoul National University Hospital selects RayCare

RaySearch Laboratories AB (publ) announces that Seoul National University Hospital (SNUH) in South Korea has placed an order for the information oncology system RayCare®*. Recently, the hospital invested in RaySearch’s treatment planning system RayStation®*.In April 2022 the carbon ion center at SNUH ordered RayStation treatment planning system, for use with their Toshiba Heavy Ion Therapy System. The hospital has now decided to invest in RayCare as their information oncology system. Carbon ion therapy is a highly advanced radiation therapy technique that can be effective for complex

Invitation - presentation of Sandvik’s report of the second quarter 2022

Sandvik will publish its second quarter results on Friday, July 15, 2022 at approximately 11:30 AM CEST. A combined webcast and conference call for investors, analysts and financial media will be held at 13:00 PM CEST. The report will be presented in a webcast and conference call by Stefan Widing, President and CEO as well as by Cecilia Felton, CFO. The presentation will be broadcasted live on our website home.sandvik Dial-in details for the conference call: SE: +46 (0) 8 505 100 31 UK: +44 (0) 207 107 06 13 US: +1 (1) 631 570 56 13 From about 12:30 PM CEST

BEWI announces acquisition of the Lithuanian insulation company BalPol

With reference to the stock exchange notice of 18 February 2022, where BEWI announced that it had entered a letter of intent to acquire 100 per cent of a Baltic insulation company, the company today announces that it has signed an agreement to acquire the Lithuanian insulation company UAB Baltijos Polistirenas (“BalPol”). BalPol is the market leader in Lithuania for insulation solutions from expanded polystyrene (EPS) and PIR, and for EPS packaging solutions. BalPol, which was established in 2002, has approximately 150 employees and currently operates two downstream facilities, whereas

Magnolia Bostad bringing forward publication of the half-year report until July 6, 2022

Magnolia Bostad’s half-year report will be completed earlier than expected. Therefore, the report will be published on Wednesday, July 6, 2022 at around 7.45 am CEST instead of as previously announced on Thursday, July 7, 2022.   The report will be available for reading and download at www.magnoliabostad.se     For more information, please contact: Fredrik Westin, Deputy CEO & CFOfredrik.westin@magnoliabostad.se   Marita Björk, IR and Media Manager +46 72 720 00 06, marita.bjork@magnoliabostad.se

Kemi Shipping orders eight Konecranes E-VER electric forklifts to its fleet in northern Finland

Kemi Shipping Oy, owned by Finnish Metsä Group, has ordered eight award-winning Konecranes E-VER fully electric forklifts including full service contracts for their operations in the Port of Kemi. Highly impressed with an E-VER delivered early in 2022, the Finnish logistics company is strengthening operations with an additional order. The order was received in June 2022 and will be delivered in the first half of 2023. Kemi Shipping provides a range of harbor services for customers in the region. With Metsä opening a new mill for bioproducts in the north, Kemi Shipping is taking the step

Detection Technology Plc - Managers' Transactions

Detection Technology Plc Managers’ Transactions 01 July 2022 at 12:00 (EEST) Detection Technology Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Pasi Koota Position: Member of the Board/Deputy member Issuer: Detection Technology Oyj LEI: 743700IXKYKNXJ6BFL39 Notification type: INITIAL NOTIFICATION Reference number: 17583/5/6 ____________________________________________ Transaction date: 2022-06-30 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE

BioStock: SynAct Pharma ready for phase IIb and uplisting

Recently, SynAct Pharma announced that they have submitted a Clinical Trial Application to initiate EXPAND, a phase IIb study with AP1189 in newly diagnosed patients with rheumatoid arthritis. The aim is to confirm the encouraging phase IIa results and to identify AP1189’s full efficacy potential. The company was recently also approved for listing on Nasdaq Stockholm Main Market with an expected first day of trading on July 12. BioStock got in touch with SynAct Pharma’s CEO Jeppe Øvlesen and CSO Thomas Jonassen.Read the full article at biostock.se: https://www.biostock.se/en/2022/07/

SBB divests three project properties in Sweden and an office property in Norway for approximately SEK 860 million

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) is selling three project properties for community services in Sweden to Hemsö, whereby Hemsö will take over responsibility for financing the projects and an office property in Norway with partly public tenants that is sold to local investors. ”SBB is divesting project properties that are not included in SBB's earnings capacity and is streamlining the portfolio by selling non-core holdings of office properties, which strengthens SBB's balance sheet and reduces future investment needs. It also feels very good that Hemsö is the buyer of the

Storebrand Livsforsikring AS: Danica transaction closed

Storebrand Livsforsikring AS has today acquired 100% of the shares in Danica Pensjonsforsikring AS ("Danica"), Norway, and the transaction has now been closed. For more information about the transaction, reference is made to the stock exchange notification on 20 December 2021. Lysaker, 1 July 2022 For further inquiries, please contact: Head of Investor Relations & Rating, Daniel Sundahl:daniel.sundahl@storebrand.no or (+47) 913 61 899 Media requests: SVP Communications, Margrethe Assevmargrethe.assev@storebrand.no or (+47) 951 55 056

SARS-CoV-2 vaccine study approved by Bangladesh BMRC

ISR’s application to conduct a phase I/II clinical trial of the dry powder nasal vaccine for SARS-CoV-2 in Bangladesh has been approved.“We are very happy to have received approval from BMRC NREC for our nasal vaccine trial in Bangladesh. It has been a great team effort with the National Coordinating Investigators, professor ABM Abdullah, professor Ahmedul Kabir and professor Shafiqul Islam giving great support to the work of the local CRO, BCTL and laboratory icddr,b. Our next step is to complete the final steps of drug production as part of final approval. With the support from Dr

Top 5 life science stocks – first half of 2022

For known reasons, it has been a rough first half of the year for the stock market, several of the world's leading indices lost more than twenty per cent and the Stockholm Stock Exchange followed suit. The harsh interest rate climate and the declining risk appetite had not least an effect on the life science sector, where the smaller companies were particularly affected. Despite the falling trend, some companies broke the pattern - see the list of the five best performing life science stocks here.Read the full article on biostock.se: https://www.biostock.se/en/2022/07/top-5-life-science-

Invitation to the presentation of Axfood’s second quarter 2022

Axfood invites investors, analysts and the press to a presentation of the interim report for the second quarter 2022 at 9:30 am CET on 15 July. The report will be published at 7:00 am CET the same day.Axfood’s President and CEO Klas Balkow will present the report together with CFO Anders Lexmon. The presentation will be held in English. Time: Friday, 15 July at 9:30 am CET To participate, please dial in:Sweden: +46 8 519 993 83The UK+44 333 300 9267The US: +1 646 7224 904 The presentation can also be followed live via webcast at axfood.com .

MEKO completes the acquisition of Koivunen

Today MEKO (previously Mekonomen Group) has completed the acquisition of Koivunen, the leading provider of automotive spare parts and related services in Finland and Estonia, for an enterprise value of EUR 122 million (SEK 1,280 million) on a cash and debt free basis, in accordance with the previously announced agreement dated 14 June 2022. The acquisition is financed in cash through existing liquidity and bank facilities. Koivunen will be consolidated into MEKO from 1 July 2022. Through the acquisition, MEKO expands its geographical presence in Finland and establishes itself in the

KÖPING HYDROGEN PARK’S ENVIRONMENTAL PERMIT APPLICATION PROCESS CONTINUES WITH AN OFFICIAL CONSULTATION MEETING IN KÖPING.

On the 23rd of June, Plagazi AB (publ) (“Plagazi” or the “Company”) together with the Municipality of Köping, Wescon Miljökonsult AB, the County Administrative Board of Västmanland, and Mälardalens Fire- and Rescue Association held a consultation meeting for Köping Hydrogen Park’s environmental permit application process.During the meeting, which was attended by Köping Hydrogen Park’s project group, including Plagazi, the Municipality of Köping and Wescon Miljökonsult AB, and the County Administrative Board of Västmanland together with Mälardalens Fire- and Rescue Association, many topics

Invitation to presentation of Pandox’s interim report January–June 2022

Pandox AB (publ) publishes the interim report for the period January–June 2022 on 15 July 2022, at 07:00 CEST, followed by a webcasted telephone conference at 14:00 CEST. Agenda (CEST) 07:00 – Interim report published via Cision and www.pandox.se12:00 – Presentation material published at www.pandox.se14:00 – Webcasted telephone conference with                Liia Nõu, CEO                Anneli Lindblom, CFO Afterwards, a proprietary presentation on the international hotel market, separate from Pandox’s earnings presentation, will be held by Thomas Emanuel, Senior Director,

BioStock: Ultimovacs' malignant melanoma study fully recruited

Norwegian biotech Ultimovacs shows progress in the clinical trial of malignant melanoma despite challenges caused by the pandemic. The clinical-stage leader in immune-stimulatory cancer vaccines has now reached the recruitment goal in the INITIUM phase II trial of UV1. The study provides randomised data on the effectiveness of UV1 as an add-on to standard-of-care treatment. Topline progression-free survival data is expected in H1 2023.Read the article at biostock.se : https://www.biostock.se/en/2022/07/ultimovacs-malignant-melanoma-study-fully-recruited/

THiS Group extends the subscription period in the ongoing share issuing process until September 1, 2022

The Board of Directors of THiS Less-is-more Group AB (publ) (“THiS” or the “Company”) has today decided that the subscription period for the share issuing process (the “Offer”) that the Company announced in a press release on March 31, 2022, is further extended to September 1, 2022.The reasons for the extended subscription period are as follows: · The company is currently in final negotiations and in the due diligence process with companies that THiS Group intends to acquire. By extending the subscription period, the Company has the opportunity to complete the acquisitions within the

There are no items matching the current filter
There are no more items matching the current filter
Back to top